Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by two referees whose comments are enclosed. As you will see, both referees express interest in your work, but both also raise significant concerns with the manuscript that would need to be addressed before we can consider publication here. In particular, both referees comment on the need to determine whether MYBPH also regulates ROCK2. I would also draw your attention to referee 1's first specific comment: the need to analyse metastatic potential of TTF1-overexpressing cells with or without MYBPH knockdown. Should you be able to address the concerns raised by the referees (especially, but not limited to, those outlined above), we would be happy to see a revised version of your manuscript.
I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
REFEREE REPORTS

Referee #1
This manuscript provides novel connections between the TTF-1 transcription factor and regulation of the actin cytoskeleton via the transcriptional regulation of MYBPH. The data are robustand convincing, conclusions are appropriate. Overall the manuscript is written in a clear and readable style.
The major issue with the manuscript is that the mechanism linking MYBPH with regulation of the actin cytoskeleton has been linked to inhibition of ROCK1 via direct protein-protein interaction without examining the possibility that some effects may be due to the simultaineous association and inhibition of ROCK2. Virtually all the experiments in Figure 5 that characterize the MYBPH-ROCK1 interaction should be repeated to determine whether there is an additional interaction with ROCK2. Similarly, in addition to using the non-isoform selective inhibitor Y-27632 in Figure 5I and Figure 6 , siRNA of ROCK1, ROCK2 and the combination should be undertaken to determine if one or both kinases contribut to RLC phosphorylation. Finally, given that the inhibition of ROCK1 by RhoE has been used as a paradigm, the possibility that ROCK phosphorylates MYBPH should be examined, incorporation of [32P]-ATP in the in vitro kinase assay in Figure 5G followed by radiography of the gel would be sufficient to reveal whether MYBPH were a substrate.
Referee #2
This manuscript describes the role of MYBPH in regulating actin organisation and cell migration. MYBPH is described to be a transcriptional target of Nkx2.1/TTF1 and to be a negative regulator of ROCK1. I find this work interesting and believe that it could be suitable for EMBO J following suitable additional work.
Specific comments
The authors should formally test their hypothesis that TTF1 +ve tumours may be less dangerous because MYBPH expression reduces metastatic ability. More specifically, the same sort of experiments that are used to demonstrate that high levels of MYBPH reduce metastasis should be done with cells over-expressing TTF1 with and without MYBPH shRNA. Figure 1c should include controls to demonstrate that regions away from the TTF1 binding sites are not Chip'ed with the TTF1 antibody.
The siRNA experiments need confirmation with a second independent sequence for all the key experiments. In particular, Figure 3e , Figure 5b and Figure 6a need to include a second MYBPH siRNA. Some of these data are currently in the supplementary data and need to be moved into the main figures.
Why did the authors focus on ROCK1? Does MYBPH not bind ROCK2? Is the prominent cortical F-actin ring observed in siMYBPH cells affected by interference with other MLC kinases (MRCKs, MLCK, ZIPK, Citron).
A second ROCK inhibitor (in addition to Y27632) or siRNA should be used to confirm that the effects observed following ROCK inhibition are due to inhibition of ROCK and not other 'off-target' kinases.
The authors state that GST-ROCK1 was purchased from Sigma. I expect that this was not full length. What fragment was used for the pull-downs?
The authors should determine the effect of over-expressing MYBPHdelta3 and MYBPHdelta2 on cell morphology and migration. It will be important to determine if the effects observed correlate with binding to ROCK1.
The western blots of NCI-H441 cells in Figure 5c are not convincing: there looks to be some problem with the transfer of the ROCK1 blot. Figure S10 is not convincing and should be removed. We sincerely appreciate the positive comments.
Major points: 1) The major issue with the manuscript is that the mechanism linking MYBPH with regulation of the actin cytoskeleton has been linked to inhibition of ROCK1 via direct protein-protein interaction without examining the possibility that some effects may be due to the simultaneous association and inhibition of ROCK2. Virtually all the experiments in Figure 5 that characterize the MYBPH-ROCK1 interaction should be repeated to determine whether there is an additional interaction with ROCK2.
Following the reviewer's suggestion, we performed a number of additional experiments to investigate whether MYBPH also binds to and inhibits ROCK2 in addition to ROCK1. MYBPH was consequently found to bind with ROCK1 but not appreciably with ROCK2, while in vitro kinase assays showed that ROCK1-mediated but not ROCK2-mediated phosphorylation of a myosin light chain was significantly inhibited by the presence of MYBPH in the reaction mixture. These results are now included in Figures 6C and 6D , as well as the revised text (line 5 from bottom of page 7 to line 5, page 8). Figure 5I and Figure  6 , siRNA of ROCK1, ROCK2 and the combination should be undertaken to determine if one or both kinases contribute to RLC phosphorylation.
2) Similarly, in addition to using the non-isoform selective inhibitor Y-27632 in
Following the reviewer's suggestion, we repeated a number of experiments with siROCK1 and siROCK2. While increased motility and RLC phosphorylation induced by MYBPH knockdown in NCI-H441 cells were significantly, though not completely, counteracted by simultaneous treatment with Y-27632 ( Figure 7D corresponding to Figure5I in the previous version), we found that the siMYBPH-induced changes were similarly counteracted by simultaneous treatment with siROCK1 but not siROCK2 ( Figure 7E ; lines 5-8, page 9), showing that the inhibitory activity of MYBPH on ROCK2 was negligible. Furthermore, three-dimensional invasion assay results showed that siMYBPH-induced single-cell migration was markedly counteracted by simultaneous treatment with siROCK1 ( Figure 8B , line 17-18, page 9), which was similarly observed with Y-27632 treatment ( Figure 8A corresponding to previous Figure 6A ). In this regard, we now note that our findings regarding the inhibitory activity of MYBPH biased toward ROCK1 appear to be consistent with a previous report that siRNA-mediated ROCK1 knockdown results in loss of stress fibers, in contrast to the lack of such effects in cells knocked down for ROCK2 (Yoneda A et al., J. Cell Biol. 170:443-453, 2005) . A short paragraph discussing this point has been added to the revised Discussion section (lines 9-16, page 11). Figure 5G followed by radiography of the gel would be sufficient to reveal whether MYBPH were a substrate.
3) Finally, given that the inhibition of ROCK1 by RhoE has been used as a paradigm, the possibility that ROCK phosphorylates MYBPH should be examined, incorporation of [32P]-ATP in the in vitro kinase assay in
Thank you for this insightful comment. We performed the suggested experiment, which clearly showed a lack of MYBPH phosphorylation by either ROCK1 or ROCK2. These results are now included in Supplementary Figure S8 and the revised text (lines 5-7, page 8).
To Reviewer #2:
This manuscript describes the role of MYBPH in regulating actin organisation and cell migration.
MYBPH is described to be a transcriptional target of Nkx2.1/TTF1 and to be a negative regulator of ROCK1. I find this work interesting and believe that it could be suitable for EMBO J following suitable additional work.
Thank you very much for the engouraging comments.
Specific comments 1) The authors should formally test their hypothesis that TTF1 +ve tumours may be less dangerous because MYBPH expression reduces metastatic ability. More specifically, the same sort of experiments that are used to demonstrate that high levels of MYBPH reduce metastasis should be done with cells over-expressing TTF1 with and without MYBPH shRNA.
Following the reviewer's suggestion, we performed experimental metastasis assay, essentially the same as that described by Shibue and Weinberg using the NCI-H441 lung adenocarcinoma cell line, which abundantly expresses both TTF-1 and MYBPH. We consequently found that NCI-H441 cells, which were transfected with siMYBPH labeled with Alexa Fluor 488 and injected into tail veins, could migrate into lung parenchyma significantly more frequently than those transfected with the scrambled siRNA control. These results are now included in Figures 4D and 4E , and the revised Results section (lines 16-18, page 6). Together with our previous observation that overexpression of MYBPH in a highly metastatic lung cancer cell line resulted in reduced metastasis, thiese findings further support the notion that MYBPH is functionally involved in malignant behavior of cancer cells. Figure 1c should include controls to demonstrate that regions away from the TTF1 binding sites are not Chip'ed with the TTF1 antibody.
2)
Thank you for this relevant suggestion. We performed a ChIP assay using a pair of oligonucleotide primers corresponding to an unrelated genomic region, which yeilded no amplification after IP with the anti-TTF-1 antibody. This result is now included in Figure 1C Following the reviewer's suggestion, we have included results of an additional siRNA in the main figures. Those are now presented in Figures 3E, 6B (corresponding to Figure 5B in the original version), and 8A ( Figure 6A in the original version) . In addition, we have included data obtained with an additional stable MYBPH transfectant clone in Figure 6B ( Figure 5B in the original version). These results are described in the revised Results section (lines 15-17, page 7).
4) Why did the authors focus on ROCK1? Does MYBPH not bind ROCK2? Is the prominent cortical F-actin ring observed in siMYBPH cells affected by interference with other MLC kinases (MRCKs, MLCK, ZIPK, Citron).
As noted in our response to Reviewer 1, we performed a number of additional experiments to investigate whether MYBPH also binds to and inhibits ROCK2 in addition to ROCK1. MYBPH was consequently found to bind with ROCK1 but not appreciably with ROCK2 as shown in Figure 6C , while in vitro kinase assays showed that ROCK1-mediated but not ROCK2-mediated phosphorylation of a myosin light chain was significantly inhibited by the presence of MYBPH in the reaction mixture ( Figure 6D ). These findings are presented in the revised Results section from line 5 from the bottom of page 7 to line 5, page 8.
In addition, we examined whether MYBPH binds to other myosin light chain kinases. We observed a lack of interaction of MYBPH with MLCK, MRCK, citron, and ZIPK in IP-WB analysis, suggesting that MYBPH does not affect those other myosin light chain kinase activities. Those results are now included in Supplementary Figure S11 and the revised Results section (lines 14-18, page 8).
5) A second ROCK inhibitor (in addition to Y27632) or siRNA should be used to confirm that the effects observed following ROCK inhibition are due to inhibition of ROCK and not other 'off-target' kinases.
As noted above in our response to Reviewer 1, we repeated a number of experiments with siROCK1 and siROCK2 in addition to the ROCK inhibitor, Y-27632. While increased motility and RLC phosphorylation induced by MYBPH knockdown in NCI-H441 cells were significantly, though not completely, counteracted by simultaneous treatment with Y-27632 ( Figure 7D , corresponding to Figure 5I in the original version), we found that siMYBPH-induced changes were similarly counteracted by simultaneous treatment with siROCK1 but not siROCK2 ( Figure 7E ; lines 5-8, page 9), suggesting that the inhibitory activity of MYBPH on ROCK2 was negligible. Furthermore, three-dimensional invasion assay results showed that siMYBPH-induced single-cell migration was markedly counteracted by simultaneous treatment with siROCK1 ( Figure 8B ; lines 17-18, page 9), which was similarly observed with Y-27632 treatment ( Figure 8A corresponding to Figure 6A in the original version). We have added discussion regating this point and state that our findings of the inhibitory activity of MYBPH biased towards ROCK1 appear to be consistent with a previous report that siRNA-mediated ROCK1 knockdown results in loss of stress fibers, in contrast to the lack of such effects in cells knocked down for ROCK2 (Yoneda A et al., J. Cell Biol. 170:443-453, 2005) .
6) The authors state that GST-ROCK1 was purchased from Sigma. I expect that this was not full length. What fragment was used for the pull-downs?
As pointed out by the reviewer, the GST-ROCK1 purchased from Sigma was not full-length. As an additional information regarding the portion included in the recombinant protein, we have added information in regard to the amino acids included to the revised Materials and Methods section (lines 8-9 from the bottom of page 18).
7) The authors should determine the effect of over-expressing MYBPHdelta3 and MYBPHdelta2 on cell morphology and migration. It will be important to determine if the effects observed correlate with binding to ROCK1.
Following the reviewer's suggestion, we generated MDCK stable clones overexpressing MYBPH deletion mutants and performed experiments corresponding to previous Figures 4B and 3A. We found that the induction of alterations in cell morphology and actin bundle formation as well as decrease in cell motility require the presence of a fibronectin type III domain ( Figure 7B and Supplementary Figure S13) , which is the binding site for ROCK1 ( Figure 7A ). These findings are described in the revised Results section (lines 2-7 from the bottom of page 8). Taken together, these results further highlight the importance of binding capacity to ROCK1 for the functions of MYBPH. Figure 5c are not convincing: there looks to be some problem with the transfer of the ROCK1 blot.
8) The western blots of NCI-H441 cells in
In response to the reviewer's suggestion, we repeated the experiment and those findings confirmed the previous results in a clearer manner. The replaced figure is now presented as Figure  6F . Figure S10 is not convincing and should be removed.
9)
Following the reviewer's suggestion, we have omitted Figure S10 from the revised version. Many thanks for submitting the revised version of your manuscript EMBOJ-2011-78924R to the EMBO Journal. It has now been seen again by both referees, whose (brief) comments are enclosed below. As you will see, both referees find the manuscript to be satisfactorily revised and now fully support publication. I am therefore pleased to tell you that we will be able to accept your study for publication in EMBOJ. I do just have a couple of comments from the editorial side first:
-Please can you ensure that the 'n' numbers for all experiments are clearly stated in the figure legends -most panels have this, but not all.
-The quality/resolution of some of the panels needs to be improved: specifically 6B, 6C, 7A, 7C, 8E. Please can you look into this and provide higher quality images?
-We now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide the original, uncropped and unprocessed scans of all gels used in the figures (or at least of key data panels)? These should be labelled with the appropriate figure/panel number, and should have molecular weight markers; further annotation would clearly be useful but is not essential. Ideally, we would ask for separate files for each figure panel, which you can upload as a single zip file as "source data" -via EJP. These will then appear as supplementary files and be directly linked to each relevant main figure. Please let me know if you have any questions about this policy.
Many thanks for choosing EMBOJ for publication of this study, and congratulations on a fine piece of work! Editor The EMBO Journal REFEREE REPORTS Referee #1
The authors have done quite a bit of work to address the comments of both reviewers. The revised manuscript is now acceptable for publication.
